Table II.
Baseline | Follow-up | Significance | |
---|---|---|---|
Age, mean ± SD | 13.7 ± 2.8 | 16.4 ± 3.1 | |
NIMH-TSS | 10.4 ± 3.5 | 8.7 ± 4.4 | 0.46 |
MGH-HPS | 11.4 ± 5.6 | 11.8 ± 5.7 | 0.77 |
TSC-C | 1.9 ± 0.7 | 2.0 ± 0.8 | 0.52 |
TSC-P | 1.8 ± 0.7 | 1.7 ± 0.8 | 0.89 |
MIST-Automatic Subscale | 13.5 ± 7.3 | 11.4 ± 5.9 | 0.045 |
MIST-Focused Subscale | 90.9 ± 29.4 | 91.3 ± 36.8 | 0.94 |
CDI | 8.1 ± 7.5 | 15.2 ± 12.0 | 0.0001 |
MASC | 48.1 ± 16.6 | 54.1 ± 18.4 | 0.009 |
# Pulling Sites | 1.7 ± 0.9 | 1.5 ± 1.0 | 0.22 |
Treatment, current (n (%)) | |||
Antidepressants | 15 (50%) | 9 (30%) | 0.19 |
Antipsychotic agents | 2 (7%) | 2 (7%) | 1 |
NAC | 18 (60%)* | 0 | <0.0001 |
Behavioral Therapy | 9 (30%) | 5 (18%) | 0.36 |
The primary analyses are from the end of the acute phase in the NAC trial.
Abbreviations: NIMH-TSS, National Institute of Mental Health – Trichotillomania Severity Scale; MGH-HPS, Massachusetts General Hospital – Hairpulling Scale; TSC-C,P, Trichotillomania Scale for Children – Child and Parent Versions; MIST, Milwaukee Inventory for Styles of Trichotillomania; CDI, Children’s Depression Inventory; MASC, Multidimensional Anxiety Scale for Children; NAC, N- Acetylcysteine.
All children who did not receive NAC during the double-blind phase of the trial, received NAC treatment during the follow-up period but decided to discontinue it.